Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
|Articles|December 3, 2019
Methotrexate Receives FDA Approval for Treatment of Rheumatoid Arthritis
Author(s)Jill Murphy, Assistant Editor
Officials from the FDA have approved methotrexate (RediTrex, Cumberland Pharmaceuticals) as an injection for the treatment of adult and pediatric patients with rheumatoid arthritis.
Advertisement
Officials from the FDA have approved methotrexate (RediTrex, Cumberland Pharmaceuticals) as an injection for the treatment of adult and pediatric patients with rheumatoid arthritis. The injection is also indicated for adults with psoriasis, according to the company.
Methotrexate is approved as both an oral and injectable treatment in the United States. Injectable methotrexate has been shown to result in increased efficacy, greater continuation rates, and less discomfort for patients, while oral formulations are more widely available.
Cumberland, a specialty pharmaceutical company, will launch 2 injectable methotrexate product lines within the US, with both products intended for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, and severe psoriasis.
Reference
Cumberland Pharmaceuticals receives FDA approval for RediTrex™ product line [news release]. Nashville, TN; Cumberland Pharmaceuticals: December 2, 2019. http://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-receives-fda-approval-reditrextm. Accessed December 3, 2019.
Advertisement
Related to this article
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
William J. Peppard, PharmD, explains how emerging suzetrigine findings after knee arthroplasty connect opioid stewardship with functional recovery and the pharmacist’s role in ensuring treatment access.
Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.
In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists Key to Lp(a) Counseling and Lipid Optimization
2
Butter, Beef Tallow, and LDL: Where Dietary Guidelines Diverge
3
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
4
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
5